DNAprint Genomics (DNAG)

[ann441j]

DNAP's Pre-investigational filing with FDA:

"The IEF method is used to assess the isoelectric point of PT-401 and its isoforms, which are critical in their formation because they directly impact product potency. This stage is necessary in order to prepare a successful Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), and we are pleased with KBI BioPharma's development of this third and next-to-final step."

"The IEF assay's development will contribute to the on-schedule, on-budget delivery of PT-401 as a treatment for anemia," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We believe we are just one step removed from submitting a Pre-IND package in preparation for our first meeting with the FDA."

Ann